25 XP   0   0   10

Intellia Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Intellia Therapeutics Inc together

PenkeI guess you are interested in Intellia Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Intellia Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Intellia Therapeutics Inc

I send you an email if I find something interesting about Intellia Therapeutics Inc.

Quick analysis of Intellia Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Intellia Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$10.93
Expected worth in 1 year
$9.00
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
$-1.93
Return On Investment
-8.9%

For what price can you sell your share?

Current Price per Share
$21.57
Expected price per share
$0 - $23.63
How sure are you?
50%

1. Valuation of Intellia Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$21.57

Intrinsic Value Per Share

$-52.92 - $-62.18

Total Value Per Share

$-42.00 - $-51.26

2. Growth of Intellia Therapeutics Inc (5 min.)




Is Intellia Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$973.7m$122.1m11.1%

How much money is Intellia Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$117.6m-$118.7m$1.1m0.9%
Net Profit Margin1,058.1%-929.2%--

How much money comes from the company's main activities?

3. Financial Health of Intellia Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#52 / 1016

Most Revenue
#309 / 1016

Most Profit
#986 / 1016

Most Efficient
#17 / 1016

What can you expect buying and holding a share of Intellia Therapeutics Inc? (5 min.)

Welcome investor! Intellia Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Intellia Therapeutics Inc.

What can you expect buying and holding a share of Intellia Therapeutics Inc?

First you should know what it really means to hold a share of Intellia Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Intellia Therapeutics Inc is $21.57. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Intellia Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Intellia Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $10.93. Based on the TTM, the Book Value Change Per Share is $-0.48 per quarter. Based on the YOY, the Book Value Change Per Share is $0.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Intellia Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.38-6.4%-1.25-5.8%-1.23-5.7%-0.76-3.5%-0.49-2.3%
Usd Book Value Change Per Share0.130.6%-0.48-2.2%0.512.4%0.401.9%0.301.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.130.6%-0.48-2.2%0.512.4%0.401.9%0.301.4%
Usd Price Per Share30.49-35.04-53.82-50.95-33.39-
Price to Earnings Ratio-5.54--7.09--10.88--19.16--19.40-
Price-to-Total Gains Ratio229.74-14.76--59.32--80.61--101.50-
Price to Book Ratio2.79-3.07-5.55-7.53-6.47-
Price-to-Total Gains Ratio229.74-14.76--59.32--80.61--101.50-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.57
Number of shares46
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.480.40
Usd Total Gains Per Share-0.480.40
Gains per Quarter (46 shares)-22.1918.48
Gains per Year (46 shares)-88.7573.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-89-9907464
20-177-1880148138
30-266-2770222212
40-355-3660296286
50-444-4550370360
60-532-5440444434
70-621-6330517508
80-710-7220591582
90-799-8110665656
100-887-9000739730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.037.00.00.0%0.037.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.022.03.032.4%12.022.03.032.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%12.022.03.032.4%12.022.03.032.4%

Fundamentals of Intellia Therapeutics Inc

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 16:15:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Intellia Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Intellia Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 6,894.2% means that $68.94 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Intellia Therapeutics Inc:

  • The MRQ is 6,894.2%. The company is making a huge profit. +2
  • The TTM is 1,058.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ6,894.2%TTM1,058.1%+5,836.0%
TTM1,058.1%YOY-929.2%+1,987.3%
TTM1,058.1%5Y-250.6%+1,308.7%
5Y-250.6%10Y-239.1%-11.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6,894.2%-199.6%+7,093.8%
TTM1,058.1%-213.0%+1,271.1%
YOY-929.2%-279.3%-649.9%
5Y-250.6%-438.4%+187.8%
10Y-239.1%-605.5%+366.4%
1.1.2. Return on Assets

Shows how efficient Intellia Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • -10.2% Return on Assets means that Intellia Therapeutics Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Intellia Therapeutics Inc:

  • The MRQ is -10.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.2%TTM-9.0%-1.2%
TTM-9.0%YOY-9.8%+0.8%
TTM-9.0%5Y-8.1%-0.9%
5Y-8.1%10Y-11.7%+3.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.2%-13.5%+3.3%
TTM-9.0%-12.9%+3.9%
YOY-9.8%-11.8%+2.0%
5Y-8.1%-14.1%+6.0%
10Y-11.7%-16.0%+4.3%
1.1.3. Return on Equity

Shows how efficient Intellia Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • -12.6% Return on Equity means Intellia Therapeutics Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Intellia Therapeutics Inc:

  • The MRQ is -12.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.6%TTM-10.8%-1.8%
TTM-10.8%YOY-12.4%+1.6%
TTM-10.8%5Y-10.2%-0.6%
5Y-10.2%10Y-15.4%+5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.6%-16.9%+4.3%
TTM-10.8%-16.1%+5.3%
YOY-12.4%-15.1%+2.7%
5Y-10.2%-19.9%+9.7%
10Y-15.4%-20.9%+5.5%

1.2. Operating Efficiency of Intellia Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Intellia Therapeutics Inc is operating .

  • Measures how much profit Intellia Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 7,297.4% means the company generated $72.97  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Intellia Therapeutics Inc:

  • The MRQ is 7,297.4%. The company is operating very efficient. +2
  • The TTM is 1,076.9%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ7,297.4%TTM1,076.9%+6,220.6%
TTM1,076.9%YOY-896.4%+1,973.2%
TTM1,076.9%5Y-246.5%+1,323.4%
5Y-246.5%10Y-242.8%-3.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7,297.4%-295.1%+7,592.5%
TTM1,076.9%-225.8%+1,302.7%
YOY-896.4%-288.4%-608.0%
5Y-246.5%-477.4%+230.9%
10Y-242.8%-625.6%+382.8%
1.2.2. Operating Ratio

Measures how efficient Intellia Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of -73.26 means that the operating costs are $-73.26 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Intellia Therapeutics Inc:

  • The MRQ is -73.261.
  • The TTM is -10.050.
Trends
Current periodCompared to+/- 
MRQ-73.261TTM-10.050-63.211
TTM-10.050YOY10.080-20.129
TTM-10.0505Y3.915-13.965
5Y3.91510Y5.012-1.097
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-73.2613.090-76.351
TTM-10.0503.264-13.314
YOY10.0803.783+6.297
5Y3.9155.679-1.764
10Y5.0127.894-2.882

1.3. Liquidity of Intellia Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Intellia Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.67 means the company has $8.67 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Intellia Therapeutics Inc:

  • The MRQ is 8.665. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.278. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.665TTM9.278-0.613
TTM9.278YOY7.585+1.693
TTM9.2785Y8.146+1.132
5Y8.14610Y8.161-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6653.914+4.751
TTM9.2784.220+5.058
YOY7.5855.388+2.197
5Y8.1466.045+2.101
10Y8.1616.406+1.755
1.3.2. Quick Ratio

Measures if Intellia Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 14.18 means the company can pay off $14.18 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Intellia Therapeutics Inc:

  • The MRQ is 14.184. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.029. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.184TTM17.029-2.845
TTM17.029YOY13.154+3.876
TTM17.0295Y14.041+2.989
5Y14.04110Y11.373+2.668
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.1843.572+10.612
TTM17.0293.998+13.031
YOY13.1545.390+7.764
5Y14.0415.969+8.072
10Y11.3736.287+5.086

1.4. Solvency of Intellia Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Intellia Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Intellia Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Intellia Therapeutics Inc assets are financed with 19.3% credit (debt) and the remaining percentage (100% - 19.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Intellia Therapeutics Inc:

  • The MRQ is 0.193. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.171. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.193TTM0.171+0.022
TTM0.171YOY0.210-0.039
TTM0.1715Y0.212-0.041
5Y0.21210Y0.260-0.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1930.336-0.143
TTM0.1710.334-0.163
YOY0.2100.269-0.059
5Y0.2120.366-0.154
10Y0.2600.390-0.130
1.4.2. Debt to Equity Ratio

Measures if Intellia Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 23.9% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Intellia Therapeutics Inc:

  • The MRQ is 0.239. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.206. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.239TTM0.206+0.032
TTM0.206YOY0.267-0.060
TTM0.2065Y0.271-0.065
5Y0.27110Y0.294-0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2390.382-0.143
TTM0.2060.396-0.190
YOY0.2670.335-0.068
5Y0.2710.434-0.163
10Y0.2940.465-0.171

2. Market Valuation of Intellia Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Intellia Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Intellia Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -5.54 means the investor is paying $-5.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Intellia Therapeutics Inc:

  • The EOD is -3.921. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.543. Based on the earnings, the company is expensive. -2
  • The TTM is -7.091. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.921MRQ-5.543+1.622
MRQ-5.543TTM-7.091+1.548
TTM-7.091YOY-10.877+3.786
TTM-7.0915Y-19.156+12.065
5Y-19.15610Y-19.401+0.245
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.921-2.259-1.662
MRQ-5.543-2.569-2.974
TTM-7.091-2.664-4.427
YOY-10.877-4.120-6.757
5Y-19.156-6.258-12.898
10Y-19.401-6.171-13.230
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Intellia Therapeutics Inc:

  • The EOD is -5.480. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.746. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.300. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.480MRQ-7.746+2.266
MRQ-7.746TTM-8.300+0.554
TTM-8.300YOY-13.249+4.949
TTM-8.3005Y-19.395+11.094
5Y-19.39510Y-18.285-1.110
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.480-2.924-2.556
MRQ-7.746-3.246-4.500
TTM-8.300-3.488-4.812
YOY-13.249-5.620-7.629
5Y-19.395-8.315-11.080
10Y-18.285-8.826-9.459
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Intellia Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.79 means the investor is paying $2.79 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Intellia Therapeutics Inc:

  • The EOD is 1.974. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.790. Based on the equity, the company is underpriced. +1
  • The TTM is 3.069. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.974MRQ2.790-0.816
MRQ2.790TTM3.069-0.278
TTM3.069YOY5.551-2.483
TTM3.0695Y7.530-4.461
5Y7.53010Y6.471+1.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9741.851+0.123
MRQ2.7902.090+0.700
TTM3.0692.095+0.974
YOY5.5512.844+2.707
5Y7.5303.466+4.064
10Y6.4713.815+2.656
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Intellia Therapeutics Inc.

3.1. Institutions holding Intellia Therapeutics Inc

Institutions are holding 87.337% of the shares of Intellia Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31ARK Investment Management LLC11.87482.060111412449146382014.7138
2023-12-31BlackRock Inc9.37570.007901069587790510.7946
2023-12-31Vanguard Group Inc8.68560.005683474491555791.8992
2023-12-31State Street Corporation4.92770.0074735861100293626.8673
2023-12-31Nikko Asset Management Americas Inc3.61951.01853478562-41733-1.1855
2023-12-31Sumitomo Mitsui Trust Holdings Inc3.61950.07843478562-41733-1.1855
2023-12-31Morgan Stanley - Brokerage Accounts2.64810.00682545022-545919-17.6619
2023-12-31Wellington Management Company LLP2.55650.0142456917-195077-7.3559
2023-12-31Deep Track Capital, LP2.34122.2911225000025000012.5
2023-12-31Federated Hermes Inc2.0980.1526201630024472213.8138
2023-12-31Geode Capital Management, LLC2.05320.00631973269930244.9474
2023-09-30Citadel Advisors Llc2.050.0134197018336555522.7813
2023-12-31T. Rowe Price Associates, Inc.1.90850.00751834143-215077-10.4956
2023-12-31AllianceBernstein L.P.1.73110.019516637421166307.5386
2023-12-31Goldman Sachs Group Inc1.71590.00451649054852791107.0992
2023-12-31Rokos Capital Management LLP1.52290.38921463630743345.3505
2023-12-31Casdin Capital, LLC1.50874.3397145000027192523.0821
2023-12-31FMR Inc1.23470.00281186603-306425-20.5237
2023-12-31Dimensional Fund Advisors, Inc.1.21830.01041170829607485.4724
2023-12-31Himension Fund1.07242.85311030621-114470-9.9966
Total 67.762313.287565123891+4369535+6.7%

3.2. Funds holding Intellia Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28ARK Innovation ETF8.07562.74667761172-45018-0.5767
2024-03-31ARK Disruptive Innovation Full Composite8.05482.74267741156-318377-3.9503
2024-02-29Vanguard Total Stock Mkt Idx Inv2.73840.00552631770-11476-0.4342
2024-03-28SPDR® S&P Biotech ETF2.65260.92882549283321601.2776
2024-03-31ARK Genomic Revolution2.41993.9812325655-95670-3.9511
2024-03-28ARK Genomic Revolution ETF2.41343.9828231941800
2024-02-29Nikko AM ARK Disruptive Innovation A USD2.34582.34052254501-23709-1.0407
2024-03-28iShares Russell 2000 ETF2.29390.09262204620137780.6289
2024-02-29Vanguard Small Cap Index2.28170.05012192902202890.9339
2023-12-31Vanguard Health Care Inv1.59680.1008153465100
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.37190.0415131847555190.4203
2024-02-29Vanguard Small Cap Growth Index Inv1.28060.11331230775204101.6863
2023-12-31Federated Hermes Kaufmann Small Cap Grow1.04160.72571001000380003.946
2023-12-31Federated Hermes Kaufmann Small Cap A1.04160.72571001000380003.946
2023-12-31Federated Hermes Kaufmann Growth1.03010.61999000020152325.5585
2023-12-31Federated Hermes Kaufmann R1.03010.618999000020152325.5585
2024-01-31Fidelity Small Cap Index0.92850.0857892321149071.699
2023-12-31T. Rowe Price New Horizons0.86220.1021828664-86955-9.4969
2023-12-31US Small-Cap Growth II Equity Comp0.86220.1018828664-86955-9.4969
2024-02-29Fidelity Select Biotechnology0.85690.53882350100
Total 45.178620.64343419528-82051-0.2%

3.3. Insider Transactions

Insiders are holding 1.334% of the shares of Intellia Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-04James BastaSELL229732.99
2024-01-08Laura Sepp-lorenzinoSELL227528.87
2024-01-03David LebwohlSELL584329.46
2024-01-03Glenn GoddardSELL536529.46
2024-01-03John M LeonardSELL1922329.46
2023-10-31Muna BhanjiSELL26523.9
2023-07-31Muna BhanjiSELL26542.33
2023-07-06Muna BhanjiSELL186739.3
2023-07-03Eliana ClarkSELL36040.51
2023-06-20Eliana ClarkSELL500045

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Intellia Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.133-0.482+463%0.508-74%0.402-67%0.295-55%
Book Value Per Share--10.92711.402-4%10.132+8%7.288+50%4.699+133%
Current Ratio--8.6659.278-7%7.585+14%8.146+6%8.161+6%
Debt To Asset Ratio--0.1930.171+13%0.210-8%0.212-9%0.260-26%
Debt To Equity Ratio--0.2390.206+16%0.267-10%0.271-12%0.294-19%
Dividend Per Share----0%-0%-0%-0%
Eps---1.375-1.252-9%-1.233-10%-0.758-45%-0.491-64%
Free Cash Flow Per Share---0.984-1.062+8%-1.019+4%-0.625-37%-0.372-62%
Free Cash Flow To Equity Per Share--0.124-0.723+683%0.498-75%0.363-66%0.286-57%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---62.185--------
Intrinsic Value_10Y_min---52.923--------
Intrinsic Value_1Y_max---3.985--------
Intrinsic Value_1Y_min---3.913--------
Intrinsic Value_3Y_max---13.686--------
Intrinsic Value_3Y_min---13.031--------
Intrinsic Value_5Y_max---25.450--------
Intrinsic Value_5Y_min---23.475--------
Market Cap2073015048.000-41%2930284136.0003367568256.000-13%5172446448.000-43%4896597053.400-40%3208797885.730-9%
Net Profit Margin--68.94210.581+552%-9.292+113%-2.506+104%-2.391+103%
Operating Margin--72.97410.769+578%-8.964+112%-2.465+103%-2.428+103%
Operating Ratio---73.261-10.050-86%10.080-827%3.915-1971%5.012-1562%
Pb Ratio1.974-41%2.7903.069-9%5.551-50%7.530-63%6.471-57%
Pe Ratio-3.921+29%-5.543-7.091+28%-10.877+96%-19.156+246%-19.401+250%
Price Per Share21.570-41%30.49035.040-13%53.820-43%50.950-40%33.388-9%
Price To Free Cash Flow Ratio-5.480+29%-7.746-8.300+7%-13.249+71%-19.395+150%-18.285+136%
Price To Total Gains Ratio162.526-41%229.73614.761+1456%-59.318+126%-80.613+135%-101.496+144%
Quick Ratio--14.18417.029-17%13.154+8%14.041+1%11.373+25%
Return On Assets---0.102-0.090-12%-0.098-4%-0.081-21%-0.117+15%
Return On Equity---0.126-0.108-14%-0.124-1%-0.102-19%-0.154+22%
Total Gains Per Share--0.133-0.482+463%0.508-74%0.402-67%0.295-55%
Usd Book Value--1050169000.0001095828500.000-4%973709000.000+8%700447650.000+50%451646783.784+133%
Usd Book Value Change Per Share--0.133-0.482+463%0.508-74%0.402-67%0.295-55%
Usd Book Value Per Share--10.92711.402-4%10.132+8%7.288+50%4.699+133%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.375-1.252-9%-1.233-10%-0.758-45%-0.491-64%
Usd Free Cash Flow---94574000.000-102017750.000+8%-97919250.000+4%-60053250.000-37%-35738256.757-62%
Usd Free Cash Flow Per Share---0.984-1.062+8%-1.019+4%-0.625-37%-0.372-62%
Usd Free Cash Flow To Equity Per Share--0.124-0.723+683%0.498-75%0.363-66%0.286-57%
Usd Market Cap2073015048.000-41%2930284136.0003367568256.000-13%5172446448.000-43%4896597053.400-40%3208797885.730-9%
Usd Price Per Share21.570-41%30.49035.040-13%53.820-43%50.950-40%33.388-9%
Usd Profit---132161000.000-117602500.000-11%-118714500.000-10%-72346200.000-45%-44814851.351-66%
Usd Revenue---1917000.0009068750.000-121%13030250.000-115%11127300.000-117%8151891.892-124%
Usd Total Gains Per Share--0.133-0.482+463%0.508-74%0.402-67%0.295-55%
 EOD+2 -6MRQTTM+15 -18YOY+16 -175Y+13 -2010Y+15 -18

4.2. Fundamental Score

Let's check the fundamental score of Intellia Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.921
Price to Book Ratio (EOD)Between0-11.974
Net Profit Margin (MRQ)Greater than068.942
Operating Margin (MRQ)Greater than072.974
Quick Ratio (MRQ)Greater than114.184
Current Ratio (MRQ)Greater than18.665
Debt to Asset Ratio (MRQ)Less than10.193
Debt to Equity Ratio (MRQ)Less than10.239
Return on Equity (MRQ)Greater than0.15-0.126
Return on Assets (MRQ)Greater than0.05-0.102
Total6/10 (60.0%)

4.3. Technical Score

Let's check the technical score of Intellia Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.670
Ma 20Greater thanMa 5024.816
Ma 50Greater thanMa 10027.219
Ma 100Greater thanMa 20027.878
OpenGreater thanClose21.220
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  11,542-98610,55686811,424-1,7229,702-14,085-4,383
Total Revenue 13,573-96712,60698813,594-1,60211,992-13,909-1,917



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,300,977
Total Liabilities250,808
Total Stockholder Equity1,050,169
 As reported
Total Liabilities 250,808
Total Stockholder Equity+ 1,050,169
Total Assets = 1,300,977

Assets

Total Assets1,300,977
Total Current Assets998,330
Long-term Assets302,647
Total Current Assets
Cash And Cash Equivalents 226,748
Short-term Investments 685,475
Net Receivables 36,456
Other Current Assets 49,651
Total Current Assets  (as reported)998,330
Total Current Assets  (calculated)998,330
+/-0
Long-term Assets
Property Plant Equipment 148,135
Long Term Investments 154,512
Long-term Assets  (as reported)302,647
Long-term Assets  (calculated)302,647
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities115,208
Long-term Liabilities135,600
Total Stockholder Equity1,050,169
Total Current Liabilities
Short-term Debt 18,599
Accounts payable 7,452
Other Current Liabilities 67,017
Total Current Liabilities  (as reported)115,208
Total Current Liabilities  (calculated)93,068
+/- 22,140
Long-term Liabilities
Capital Lease Obligations 115,346
Long-term Liabilities  (as reported)135,600
Long-term Liabilities  (calculated)115,346
+/- 20,254
Total Stockholder Equity
Common Stock9
Retained Earnings -1,658,379
Accumulated Other Comprehensive Income -2,258
Other Stockholders Equity 2,710,797
Total Stockholder Equity (as reported)1,050,169
Total Stockholder Equity (calculated)1,050,169
+/-0
Other
Capital Stock9
Cash and Short Term Investments 912,223
Common Stock Shares Outstanding 90,461
Current Deferred Revenue22,140
Liabilities and Stockholders Equity 1,300,977
Net Debt -111,402
Net Invested Capital 1,050,169
Net Working Capital 883,122
Property Plant and Equipment Gross 187,996
Short Long Term Debt Total 115,346



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
10,694
0
0
0
82,139
75,540
310,624
301,469
298,969
279,263
264,975
249,170
376,235
359,545
339,778
321,233
347,315
344,363
352,441
346,635
334,280
314,752
490,830
458,555
676,322
716,891
672,243
1,334,961
1,294,464
1,202,788
1,110,424
1,084,458
1,520,114
1,417,889
1,323,240
1,243,349
1,300,977
1,300,9771,243,3491,323,2401,417,8891,520,1141,084,4581,110,4241,202,7881,294,4641,334,961672,243716,891676,322458,555490,830314,752334,280346,635352,441344,363347,315321,233339,778359,545376,235249,170264,975279,263298,969301,469310,62475,54082,13900010,694
   > Total Current Assets 
10,130
0
0
0
77,626
65,937
302,904
292,702
281,306
261,078
245,919
229,053
354,830
337,720
317,629
298,829
324,977
303,693
307,137
295,935
289,481
269,760
446,367
416,250
597,371
601,084
549,404
814,774
769,303
875,367
895,433
858,947
1,216,797
963,671
939,615
893,493
998,330
998,330893,493939,615963,6711,216,797858,947895,433875,367769,303814,774549,404601,084597,371416,250446,367269,760289,481295,935307,137303,693324,977298,829317,629337,720354,830229,053245,919261,078281,306292,702302,90465,93777,62600010,130
       Cash And Cash Equivalents 
9,845
0
0
0
75,816
64,192
300,687
290,618
273,064
257,551
241,047
222,264
340,678
327,778
305,538
293,248
58,856
47,097
49,140
38,440
57,226
80,993
361,687
179,746
160,020
141,538
129,879
334,736
123,406
133,382
147,781
141,194
523,506
294,150
171,806
168,027
226,748
226,748168,027171,806294,150523,506141,194147,781133,382123,406334,736129,879141,538160,020179,746361,68780,99357,22638,44049,14047,09758,856293,248305,538327,778340,678222,264241,047257,551273,064290,618300,68764,19275,8160009,845
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
255,203
249,485
221,959
247,482
222,500
169,266
75,117
228,201
437,351
442,525
399,140
463,531
625,282
721,869
726,494
687,000
669,116
639,392
736,268
686,761
685,475
685,475686,761736,268639,392669,116687,000726,494721,869625,282463,531399,140442,525437,351228,20175,117169,266222,500247,482221,959249,485255,2030000000000000000
       Net Receivables 
0
0
0
0
1,000
1,000
1,000
1,112
6,454
2,443
2,764
4,493
10,471
7,466
8,609
2,813
7,547
3,591
4,188
3,599
4,620
13,368
3,864
1,217
2,130
953
1,993
2,491
2,031
1,801
2,854
4,023
3,768
4,906
5,056
6,491
36,456
36,4566,4915,0564,9063,7684,0232,8541,8012,0312,4911,9939532,1301,2173,86413,3684,6203,5994,1883,5917,5472,8138,6097,46610,4714,4932,7642,4436,4541,1121,0001,0001,0000000
       Other Current Assets 
285
0
0
0
810
745
1,217
972
1,788
1,084
2,108
2,296
3,681
2,476
3,482
2,768
3,371
3,520
27,140
6,414
5,135
6,133
5,699
7,086
17,016
16,068
18,392
14,016
18,584
18,315
18,304
26,730
20,407
25,223
26,485
32,214
49,651
49,65132,21426,48525,22320,40726,73018,30418,31518,58414,01618,39216,06817,0167,0865,6996,1335,1356,41427,1403,5203,3712,7683,4822,4763,6812,2962,1081,0841,7889721,217745810000285
   > Long-term Assets 
0
0
0
0
4,513
9,603
7,720
8,767
17,663
18,185
19,056
20,117
21,405
21,825
22,149
22,404
22,338
40,670
45,304
50,700
44,799
44,992
44,463
42,305
78,951
115,807
122,839
520,187
525,161
327,421
214,991
225,511
303,317
454,218
383,625
349,856
302,647
302,647349,856383,625454,218303,317225,511214,991327,421525,161520,187122,839115,80778,95142,30544,46344,99244,79950,70045,30440,67022,33822,40422,14921,82521,40520,11719,05618,18517,6638,7677,7209,6034,5130000
       Property Plant Equipment 
308
0
0
0
2,708
4,228
4,421
5,492
10,628
11,418
12,578
13,560
15,272
16,010
16,580
16,935
17,061
37,681
37,617
37,869
37,133
42,169
39,871
37,822
55,057
94,069
95,600
101,734
100,111
100,170
99,643
127,887
160,997
159,871
156,744
152,575
148,135
148,135152,575156,744159,871160,997127,88799,643100,170100,111101,73495,60094,06955,05737,82239,87142,16937,13337,86937,61737,68117,06116,93516,58016,01015,27213,56012,57811,41810,6285,4924,4214,2282,708000308
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,739
9,868
4,746
0
0
0
0
16,735
22,262
413,288
425,050
227,251
115,348
97,624
142,320
294,347
226,881
197,281
154,512
154,512197,281226,881294,347142,32097,624115,348227,251425,050413,28822,26216,73500004,7469,8684,739000000000000000000
       Long-term Assets Other 
0
0
0
0
1,805
5,375
3,299
3,275
7,035
6,767
6,478
6,557
6,133
5,815
5,569
5,469
5,277
2,989
2,948
2,963
2,920
2,823
4,592
4,483
23,894
5,003
4,977
5,165
87,689
76,473
82,744
77,091
72,982
253,427
185,850
154,918
0
0154,918185,850253,42772,98277,09182,74476,47387,6895,1654,9775,00323,8944,4834,5922,8232,9202,9632,9482,9895,2775,4695,5695,8156,1336,5576,4786,7677,0353,2753,2995,3751,8050000
> Total Liabilities 
3,128
0
0
0
14,783
102,682
87,022
83,345
89,132
79,380
77,390
73,323
75,638
64,046
60,442
57,963
69,395
80,025
75,575
70,983
64,399
66,993
139,243
128,935
149,250
171,018
177,430
227,863
254,220
249,034
229,877
259,507
284,530
227,046
218,352
205,935
250,808
250,808205,935218,352227,046284,530259,507229,877249,034254,220227,863177,430171,018149,250128,935139,24366,99364,39970,98375,57580,02569,39557,96360,44264,04675,63873,32377,39079,38089,13283,34587,022102,68214,7830003,128
   > Total Current Liabilities 
2,355
0
0
0
10,695
10,960
21,617
22,633
30,730
24,910
26,371
25,786
31,359
25,583
25,169
25,915
40,572
39,234
38,463
37,519
35,633
35,304
59,142
55,865
64,254
60,702
73,963
97,567
125,833
126,111
123,760
131,132
126,554
103,383
99,851
91,953
115,208
115,20891,95399,851103,383126,554131,132123,760126,111125,83397,56773,96360,70264,25455,86559,14235,30435,63337,51938,46339,23440,57225,91525,16925,58331,35925,78626,37124,91030,73022,63321,61710,96010,6950002,355
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,381
5,065
5,505
5,745
5,693
5,834
6,198
5,696
8,255
7,415
8,705
9,112
9,338
9,568
13,551
16,685
16,328
16,750
17,074
18,599
18,59917,07416,75016,32816,68513,5519,5689,3389,1128,7057,4158,2555,6966,1985,8345,6935,7455,5055,0654,38100000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,381
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004,38100000000000000000
       Accounts payable 
199
0
0
0
1,360
1,206
1,042
657
4,652
1,434
2,267
2,194
2,172
1,916
335
1,754
2,708
3,687
1,848
4,548
3,941
3,870
7
7,775
10,460
8,688
6,854
7,470
9,653
10,138
7,515
4,384
5,154
6,890
11,634
3,553
7,452
7,4523,55311,6346,8905,1544,3847,51510,1389,6537,4706,8548,68810,4607,77573,8703,9414,5481,8483,6872,7081,7543351,9162,1722,1942,2671,4344,6526571,0421,2061,360000199
       Other Current Liabilities 
2,156
0
0
0
2,788
2,973
4,288
4,810
5,900
3,559
5,312
5,939
7,999
6,605
9,156
9,893
10,742
7,735
11,898
11,644
13,273
13,102
15,374
19,348
25,554
21,215
37,150
24,633
43,309
42,876
44,871
58,379
60,876
44,822
49,534
57,979
67,017
67,01757,97949,53444,82260,87658,37944,87142,87643,30924,63337,15021,21525,55419,34815,37413,10213,27311,64411,8987,73510,7429,8939,1566,6057,9995,9395,3123,5595,9004,8104,2882,9732,7880002,156
   > Long-term Liabilities 
0
0
0
0
4,088
91,722
65,405
60,712
58,402
54,470
51,019
47,537
44,279
38,463
35,273
32,048
28,823
40,791
37,112
33,464
28,766
31,689
80,101
73,070
84,996
110,316
103,467
130,296
128,387
122,923
106,117
128,375
157,976
123,663
118,501
113,982
135,600
135,600113,982118,501123,663157,976128,375106,117122,923128,387130,296103,467110,31684,99673,07080,10131,68928,76633,46437,11240,79128,82332,04835,27338,46344,27947,53751,01954,47058,40260,71265,40591,7224,0880000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,132
14,604
14,142
12,630
18,669
17,349
16,000
33,609
64,487
63,259
67,273
64,911
62,480
59,997
84,097
114,018
109,801
105,582
101,263
96,747
96,747101,263105,582109,801114,01884,09759,99762,48064,91167,27363,25964,48733,60916,00017,34918,66912,63014,14214,60415,13200000000000000000
       Warrants
0
0
0
0
0
88,620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000088,62000000
       Long-term Liabilities Other 
0
0
0
0
0
349
363
306
293
378
234
201
168
131
92
52
13
15,132
0
0
0
0
0
0
0
0
0
0
0
10,962
10,790
18,600
24,026
0
0
0
0
000024,02618,60010,79010,9620000000000015,13213529213116820123437829330636334900000
       Deferred Long Term Liability 
0
0
0
0
3,765
2,753
65,042
60,406
58,109
54,092
50,785
47,336
44,111
38,332
35,181
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000035,18138,33244,11147,33650,78554,09258,10960,40665,0422,7533,7650000
> Total Stockholder Equity
7,566
0
0
0
67,356
-27,142
223,602
218,124
209,837
199,883
187,585
175,847
300,597
295,499
279,336
263,270
277,920
264,338
276,866
275,652
269,881
247,759
351,587
329,620
527,072
545,873
494,813
1,107,098
1,040,244
953,754
880,547
824,951
1,235,584
1,190,843
1,104,888
1,037,414
1,050,169
1,050,1691,037,4141,104,8881,190,8431,235,584824,951880,547953,7541,040,2441,107,098494,813545,873527,072329,620351,587247,759269,881275,652276,866264,338277,920263,270279,336295,499300,597175,847187,585199,883209,837218,124223,602-27,14267,3560007,566
   Common Stock
607
0
0
0
3
0
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
6
7
7
7
7
7
8
8
8
9
9
9
9
9
999998887777766555555444444444403000607
   Retained Earnings Total Equity000-1,280,313-1,177,187-1,063,780-950,551-849,873-703,001-621,764-550,120-481,314-435,109-392,917-365,077-332,684-300,878-272,602-248,968-223,285-201,025-181,959-159,257-137,038-121,113-97,150-81,794-66,201-53,570-43,007-35,525-28,62500000
   Accumulated Other Comprehensive Income 
0
0
0
0
-331
0
0
0
-1,430
-1,430
0
0
-4,329
-4,329
0
0
-28
59
255
336
261
373
155
31
1
-12
-13
-174
-2,632
-8,062
-9,554
-9,368
-7,461
-2,678
-3,868
-3,572
-2,258
-2,258-3,572-3,868-2,678-7,461-9,368-9,554-8,062-2,632-174-13-1213115537326133625559-2800-4,329-4,32900-1,430-1,430000-3310000
   Capital Surplus 
0
0
0
0
0
1,483
259,123
261,127
263,403
266,080
269,375
272,993
421,706
432,533
438,589
445,225
478,968
487,559
525,574
547,913
570,493
580,065
716,503
722,500
962,173
1,027,192
1,044,939
1,729,029
1,745,870
1,811,681
1,840,644
1,898,091
2,420,223
2,473,825
0
0
0
0002,473,8252,420,2231,898,0911,840,6441,811,6811,745,8701,729,0291,044,9391,027,192962,173722,500716,503580,065570,493547,913525,574487,559478,968445,225438,589432,533421,706272,993269,375266,080263,403261,127259,1231,48300000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
50
0
0
0
89,289
-87,137
259,123
261,127
263,403
266,080
269,375
272,993
421,706
432,533
438,589
445,225
478,968
487,559
525,574
547,913
570,493
580,065
716,503
722,500
962,173
1,027,192
1,044,939
1,729,029
1,745,870
1,811,681
1,840,644
1,898,091
2,420,223
2,473,825
2,512,741
2,567,195
2,710,797
2,710,7972,567,1952,512,7412,473,8252,420,2231,898,0911,840,6441,811,6811,745,8701,729,0291,044,9391,027,192962,173722,500716,503580,065570,493547,913525,574487,559478,968445,225438,589432,533421,706272,993269,375266,080263,403261,127259,123-87,13789,28900050



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue36,275
Cost of Revenue-8,976
Gross Profit27,29927,299
 
Operating Income (+$)
Gross Profit27,299
Operating Expense-551,566
Operating Income-515,291-524,267
 
Operating Expense (+$)
Research Development435,069
Selling General Administrative116,497
Selling And Marketing Expenses0
Operating Expense551,566551,566
 
Net Interest Income (+$)
Interest Income49,832
Interest Expense-0
Other Finance Cost-0
Net Interest Income49,832
 
Pretax Income (+$)
Operating Income-515,291
Net Interest Income49,832
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-481,192-499,558
EBIT - interestExpense = -515,191
-530,924
-481,192
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-515,191-481,192
Earnings Before Interest and Taxes (EBITDA)-506,215
 
After tax Income (+$)
Income Before Tax-481,192
Tax Provision-0
Net Income From Continuing Ops-481,192-481,192
Net Income-481,192
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses551,566
Total Other Income/Expenses Net-15,733-49,832
 

Technical Analysis of Intellia Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Intellia Therapeutics Inc. The general trend of Intellia Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Intellia Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Intellia Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 22.67 < 22.81 < 23.63.

The bearish price targets are: .

Tweet this
Intellia Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Intellia Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Intellia Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Intellia Therapeutics Inc. The current macd is -1.59956144.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Intellia Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Intellia Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Intellia Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Intellia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartIntellia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Intellia Therapeutics Inc. The current adx is 23.94.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Intellia Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Intellia Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Intellia Therapeutics Inc. The current sar is 25.02.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Intellia Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Intellia Therapeutics Inc. The current rsi is 28.67. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 2/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending up: The RSI is trending up. +1
Intellia Therapeutics Inc Daily Relative Strength Index (RSI) ChartIntellia Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Intellia Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Intellia Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Intellia Therapeutics Inc Daily Stochastic Oscillator ChartIntellia Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Intellia Therapeutics Inc. The current cci is -155.91953267.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Intellia Therapeutics Inc Daily Commodity Channel Index (CCI) ChartIntellia Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Intellia Therapeutics Inc. The current cmo is -53.78506032.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Intellia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartIntellia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Intellia Therapeutics Inc. The current willr is -85.89285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Intellia Therapeutics Inc Daily Williams %R ChartIntellia Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Intellia Therapeutics Inc.

Intellia Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Intellia Therapeutics Inc. The current atr is 1.22145489.

Intellia Therapeutics Inc Daily Average True Range (ATR) ChartIntellia Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Intellia Therapeutics Inc. The current obv is -31,730,287.

Intellia Therapeutics Inc Daily On-Balance Volume (OBV) ChartIntellia Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Intellia Therapeutics Inc. The current mfi is 27.22.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Intellia Therapeutics Inc Daily Money Flow Index (MFI) ChartIntellia Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Intellia Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Intellia Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Intellia Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.670
Ma 20Greater thanMa 5024.816
Ma 50Greater thanMa 10027.219
Ma 100Greater thanMa 20027.878
OpenGreater thanClose21.220
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Intellia Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Intellia Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Intellia Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Intellia Therapeutics Inc

I send you an email if I find something interesting about Intellia Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Intellia Therapeutics Inc.

Receive notifications about Intellia Therapeutics Inc in your mailbox!